共 65 条
[1]
Barber RM(2022)Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis Lancet 399 2351-2380
[2]
Sorensen RJD(2022)Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Nature 602 657-663
[3]
Pigott DM(2022)Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Nature 603 679-686
[4]
Cao YL(2022)Oral antiviral treatments for COVID-19: opportunities and challenges Pharmacol Rep 74 1255-1278
[5]
Wang J(2022)Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19 N Engl J Med 386 1397-1408
[6]
Jian FC(2022)Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study Lancet 400 1213-1222
[7]
Viana R(2022)Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge N Engl J Med 387 790-798
[8]
Moyo S(2023)Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients Clin Infect Dis 76 e342-e349
[9]
Amoako DG(2023)Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis J Med Virol 95 2540-271
[10]
Rahmah L(2022)Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir Viruses 14 257-199